V.I. Kuznetsov - Dr. Sc. (Med.), Professor, Honorary Doctor of the Russian Federation, Department of General Practice, Peoples - Friendship University of Russia (Moscow) B.B. Radysh - Dr.Sc. (Med.), Head of the Gerontology-s Department, Peoples - Frendship University of Russia (Moscow). E-mail: bobrat@rambler.ru E.A. Basova - Resident, the Department of General Practice, Peoples - Friendship University of RussiaE-mail: incadessence@inbox.ru I.S. Katkova -Ph.D. (Med.), Deputy Head Physician in the Temporary Disability-s Expertise, Doctor of Functional Diagnos-tics, City Hospital № 25 (Moscow) S.L. Safaryan - Head Physician, Consultative-Diagnostic Polyclinic № 121 (Moscow). E-mail: kdp121@uzaomed.ru N.V. Denisova - Deputy Head Physician, Consultative-Diagnostic Polyclinic № 121, Fil. № 5 (Moscow)

Moxonidine (physiotens, moxogamma) and rilmenidine (albarel, tenaxum) are the main agents of agonists I1-imidazoline receptors, the last generation of centrally acting antihypertensive drugs. These agonists have little influence on alpha2-adrenergic receptors and so the side effects typical for alpha2-adrenergic agonists (sedative effect, dry mouth, bradycardia, stuffiness in nose, abstinence syndrome, rebound syndrome) appear minimally. According to recommendations ECS 2013 and RMSAH 2013 agonists I1-imidazoline receptors are not the medicines of the first line for the treatment of arterial hypertension (AH). These agonists are prescribed in combination with other antihy-pertensive drugs if the effect of the therapy is insufficient. The effect of moxonidine begins in 30 minutes, so it can be used as the drug of the emergency help in case of the hypertension stroke. Nowadays AH in combination with the metabolic syndrome is one of the main therapeutic indications for moxonidine and rilmenidine. These drugs are effective in treatment of patients with diabetes mellitus because of the beneficial effects on insulin sensitivity. The agonists I1-imidazoline receptors are proved to have the nephroprotective effect owing to the reduc-tion of microalbuminuria. These agonists are used for the treatment of the refractory hypertension. Moxonidine can be recommended as the preven-tion of the paroxysms of fibrillation having been surgically treated in case of the combination with AH. The agonists I1-imidazoline receptors improve the life quality of the women with AH in postmenopause. Moxonidine can be recommended to the patients with the climacteric syndrome as the antihypertensive agent, because this medicine reduces such symptoms as hot flushes, palpitations, insomnia, irritability caused by the increase of the tonus of the noradrenergic and dofaminergic structures.

 

1. Edwards L.P., Brown-Bryan T.A., McLean L., Ernsberger P.Pharmacological properties of the central antihypertensive agent, moxonidine // Cardiovasc Ther.2012. V.30(4). P.199-208.
2. Sanjuliani A.F., Francischetti E.A., Genethu de Abreu V., et at.Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma atdosterone, leptin, and metabolic profile in obese hypertensive patients // Journal of Clinical and Basic Cardiotogy. 2004. Is. 1-4.P.19-25.
3. Mukaddam-Daher S.,Gutkowska J. Imidazoline receptors in the heart: a novel target and a novel mechanism of action that involves atrial natriuretic peptides // Braz. J. Med. Biol. Res.2004. V.37(8). P.1239-1245.
4. Prichard B.N., Owens C.W.,Graham B.R. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent // J. Hum. Hypertens.1997. V.11. Suppl. 1. P.S29-45.
5. Doggrell S.A. Moxonidine: some controversy // Expert Opin Pharmacother.2001. V.2(2). P.337-350.
6. Gaponova N.I.,Abdrakhmanov V.R.,Baratashvili V.L.,Tereshchenko S.N.Analysis of efficacy and safety of administration ofmoxonidinein patients with arterial hypertension and hypertensive crises // Kardiologiia.2011. V.51(6). P.91-96.
7. Sica D.A. Centrally acting anti-hypertensive agents: an update // J. Clin. Hypertens (Greenwich).2007. V.9(5). P.399-405.
8. Giannopoulos G.,Kossyvakis C.,Efremidis M., et al.Central Sympathetic Inhibition to Reduce Post-Ablation Atrial Fibrillation Recurrences in Hypertensive Patients: A Randomized Controlled Study // Circulation.2014. V.21. P.123-129.
9. Hetterich N.,Lauterbach E.,Stürer A.,Weilemann L.S.,Lauterbach M. Toxicity of antihypertensives in unintentional poisoning of young children // J. Emerg. Med.2014. V.47(2). P.155-162.
10. Kujala S.M.,Pöyhönen-Alho M,Kaaja R.J. Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women // Climacteric.2014. V.17(4). P.356-362.
11. Krespi P.G., Makris T.K., Hatzizaxarias A.N., Triposkiadis P., Tsoukala C., Kyriaki D., et al.Moxonidine effect on microalbuminuria, thrombo­modulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension// Cardiovasc Drugs Ther. 1998. V.12. P. 463-467.
12. Ruksin V.V.,Grishin O.V.,Chiritso M.M. The efficacy of antihypertension drugs and their combinations in the non-treated hypertension// Med. Tr. Prom. Ekol.2013. № 5. P.7-11.
13. Chazova I.E., Almazov V.A., Shlyakhto E.V. Moxonidine improves glycaemic control in mildy hypertensive, overweight patients: a comparison with metformin // Diabetes, Obesity and Metabolism. 2006. V.8. P.456-465.
14. Chazova I, Schlaich M.P. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY Study // International J. Hypertension. 2013. № 1. P. 1-9.
15. Sharma A.M., et al.Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study// J. Hum. Hypertens. 2004. V. 18. P. 669-675.
16. Holecki M., Dulawa J., Chulek J. Resistant hypertension in visceral obesity// Eur. J. Intern. Med. 2012. V. 23. P. 643-648.
17. Bramalage P., Pittrow D., Witchen H.U.,et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly contolled // Am. J. Hyperens. 2004. V.17. P. 904-910.
18. Jordan J., Yumuk V., Schlaich M., et al. Joint statement of the European Association for the study of the study of obesity and the European Society of Hypertension obesity and difficult to treat arerial hypertension // J. hypertens. 2012. V. 30 P. 1047-1055.
19. Engbaek M., Hjerrild M., Hallas J., Jacobsen I.A. The effect of low-dose spironolactone on resistant hypertension // J. Am. Soc. hypertens. 2010. V.4. P.290-294.
20. Tsioufis C., Kordalis A., Flessas D. et al. Pathophysiology of resistant hypertension: the role of sympathic nervous system // Int. J. Hypertens. 2011. № 2. P. 34-41.
21. SagaradS.V., Biradar-Kerure S., Ramakrishna M.R., Chaitanya K.S, Reddy S.S. A Prospective Real World Experience of Moxonidine Use in Indian Hypertensive Patients-Prescription beyond Current Guidelines// J. Clin. Diagn. Res. 2013. V. 7(10). P. 2213-2215.
22. Bousquet P., Feldman. J, Schwartz J. Central cardiovascular effects of alpha-adrenergic drugs: difference between catecholamines and Imida­zolines // J. Pharmacol. Exp. Ther. 1984. V. 230. P.232-236.
23. Podzolkov V.I., Mozharova L.G., KHomickaja JU.V.Primenenie moksonidina dlja korrekcii arterialnojj gipertonii u zhenshhin s klimaktericheskim sindromom // Kardiovaskuljarnaja terapija i profilaktika. 2005. №5. C. 83-88.
24. Cohn J.N., Pfeffer M.A., Rouleauc J., et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON) // Eur. J. Heart Fail. 2003. № 5. P. 659-667.